Tyler James Sisk, J.D., Ph.D.
With over 15 years of experience in the patent profession, Dr. Sisk specializes in numerous areas of life science subject matter including immunology, vaccines, microbiology, molecular biology and genetics, recombination technologies, and diagnostics, as well as non-life science subject matter including mechanical devices and systems and alternative energy solutions.
Dr. Sisk enjoys an extensive and successful practice of filing and prosecuting patent applications in all major marketplaces including the United States, Europe, Japan, Canada, and Australia, as well as in other smaller markets. With an acute attention to detail, Dr. Sisk contemplatively yet enthusiastically works with clients to generate effective and efficient patent filing, business negotiation, and enforcement strategies. He regularly provides freedom to operate analyses, validity and infringement opinions, and due diligence reviews for his clients.
Tyler’s formal training background is in immunology and microbiology and his PhD work related to immune system activation/regulation via transcriptional control of antigen presentation. While Tyler enjoys particular expertise regarding immunology, his knowledge base remains current in all aspects of the life sciences and has expanded to include non-life science subject matter including intelligent mechanical designs and systems.
Dr. Sisk’s clients include large, publicly traded corporations, small and mid-size biotechnology companies, universities, and manufacturing companies. He co-founded Casimir Jones, S.C. in 2007.
Founding Shareholder, Casimir Jones, S.C., 2007 to present
Associate, Medlen & Carroll, LLP, San Francisco, CA, Madison, WI, Cambridge, MA, 2004-2007
Technology Specialist, Medlen & Carroll, LLP, 2003-2004
Summer Clerkship, Medlen & Carroll, LLP, 2003
Summer Internship, Office of Technology Transfer and Corporate Research, University of Michigan, 2002
Graduate Student, Department of Microbiology and Immunology, University of Michigan Medical School, 1997-2001
Admissions Committee, Program in the Biomedical Sciences, University of Michigan Medical School, 2000-2001
Teaching Assistant, Department of Microbiology and Immunology, University of Michigan Medical School, 1997-1999
Research Associate, Department of Dairy Science, University of Wisconsin, 1996-1997
Research Specialist, Department of Anesthesiology, University of Wisconsin Medical School, 1995-1996
Ave Maria School of Law, J.D., 2004
University of Michigan, Ph.D., Microbiology and Immunology, 2001
Marquette University, B.S., Biology, 1994
Teaching and Speaking
Guest Lecturer, University of Wisconsin, Madison, Special Topics in Biomedical Engineering, BME 601, “Introduction to Patents” 2009
Guest Lecturer, University of Wisconsin, Madison, Special Topics in Biomedical Engineering, BME 601, “Introduction to Patents” 2010
Guest Lecturer, University of Michigan Medical School, Postdoctoral fellowship seminar series, “Alternative Scientific Careers, Patent Jobs” 2017
United States Patent and Trademark Office
U.S. District Court, Eastern District of Wisconsin
U.S. District Court, Western District of Wisconsin
U.S. District Court, Western District of Michigan
State Bar of Wisconsin
Sisk, T.J., Gourley, T., Roys, S. and Chang, C-H. 2000. CIITA inhibits IL-4 gene transcription by competing with NF-AT to bind CBP/p300. Journal of Immunology 165, 2511-2517.
Sisk, T.J., Nickerson, K., Inohara, N., Yee, C., Kennell, J., Cho, M-C., Yannie, J., Nunez, N. and Chang, C-H. 2001. Dendritic cell-specific MHC class II transactivator contains a caspase recruitment domain that confers potent transactivation activity. Journal of Biological Chemistry 276, 19089-19093.
Sisk, T.J., Roy, S. and Chang, C-H. 2001. Self-association of CIITA and its transactivation potential. Molecular and Cellular Biology 21, 4919-4928.
Chang, C-H., Gourley, T. and Sisk, T.J. 2002. Function and regulation of class II transactivator in the immune system. Immunologic Research; 25(2):131-42.
Sisk, T.J., Nickerson, K, Kwok, R. and Chang, C-H. 2003. Phosphorylation of class II transactivator regulates its interaction ability and transactivation function. International Immunology 15(10), 1195-1205.